For example, FGF9 promotes HAS2 expression via Wnt/β‐catenin/TCF7L2 pathway.[42] FGF9 promotes cisplatin resistance via decreased APC expression and activation of the Wnt/β‐catenin signaling pathway in colorectal cancer cells.[43] In addition, FGF9, which is considered as the downstream target gene of Wnt/β‐catenin signaling, have been reported to participate the wound repair[44] and ovarian endometrioid adenocarcinomas.[45] However, these studies did not delve into the mechanism by which FGF9 regulates the Wnt/β‐catenin signaling pathway. Here, HAS2 is linked to ovarian endometrioid adenocarcinoma.